Quantification of imatinib in human serum: Validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 699-710

  Rezende, Vinicius Marcondes ^a   Rivellis, Ariane ^a   Novaes, Mafalda Megumi Yoshinaga ^a   Chamone, Dalton de Alencar Fisher ^a   Bendit, Israel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Development; High performance liquid chromatography mass spectrometry; Imatinib; Therapeutic drug monitoring; Validation

Indexed keywords

BIOMATERIAL; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REAGENT; SOLVENT; TAMSULOSIN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ARTICLE; BIOEQUIVALENCE; CHRONIC MYELOID LEUKEMIA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG MONITORING; GOLD STANDARD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL SERVICE; HUMAN; LIMIT OF DETECTION; MASS SPECTROMETRY; PATIENT MONITORING; PLASMA; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; TREATMENT REFUSAL; VALIDATION PROCESS; BLOOD; DRUG STABILITY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; DRUG STABILITY; HUMANS; MASS SPECTROMETRY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84881293150     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S42902     Document Type: Article

References (27)

1. Druker BJ, Guilhot FO, O'Brien SG, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
2. Titier K, Picard S, Ducint D, et al. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2005;27(5):634-640.
3. Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol. 2001;28(5 Suppl 7):9-18.
4. Guilhot F, Hughes T, Cortes J, et al. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica. 2012;97(5):731-738.
5. Awidi A, Salem II, Najib N, Mefleh R, Tarawneh B. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods comparison. Leuk Res. 2010;34(6):714-717.
6. Guilhot F, Roy L, Tomowiak C. Current treatment strategies in chronic myeloid leukemia. Curr Opin Hematol. 2012;19(2):102-109.
7. Parise RA, Ramanathan RK, Hayes MJ, Egorin MJ. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;791(1-2):39-44.
8. Mičová K, Friedecký D, Faber E, Polýnková A, Adam T. Flow injection analysis vs ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma. Clin Chim Acta. 2010;411(23-24):1957-1962.
9. Roth O, Spreux-Varoquaux O, Bouchet S, et al. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC-MS/MS. Clin Chim Acta. 2010; 411(3-4):140-146.
10. Davies A, Hayes AK, Knight K, Watmough SJ, Pirmohamed M, Clark RE. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leuk Res. 2010;34(6):702-707.
11. Solassol I, Bressolle F, Philibert L, Charasson V, Astre C, Pinguet F. Liquid chromatography-electrospray mass spectrometry determination of imatinib and its main metabolite, N-desmethyl-imatinib in human plasma. J Liq Chromatogr Relat Technol. 2006;29:2957-2974.
12. Bakhtiar R, Khemani L, Hayes M, Bedman T, Tse F. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2002;28(6):1183-1194.
13. Miura M, Takahashi N, Sawada KI. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection. J Chromatogr Sci. 2011;49(5):412-415.
14. US Food and Drug Administration. Guidance for industry: bioanalytical method validation. Rockville, MD: Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2001. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf. Accessed June 6, 2013.
15. ANVISA. Resolution RE No. 899, of May 29, 2003. Brazil, Brazilian National Surveillance Agency (ANVISA); Diário Oficial da União 02/jun/2003: Available on line: http://www.in.gov.br/visualiza/index.jsp?jornal=1&pagina=56&data=02/06/2003. Accessed June 2, 2013.
16. ANVISA. Resolution RDC No. 27, of May 27, 2012. Brazil, Brazilian National Surveillance Agency (ANVISA); Diário Oficial da União 22/may/2012: Available from: http://www.in.gov.br/visualiza/index.jsp?data=22/05/2012&jornal=1&pagina=93&totalArquivos=192. Accessed June 2, 2013.
17. Vessman J, Stefan RI, Staden JF, et al. Selectivity in analytical chemistry (IUPAC Recommendations 2001). Pure Appl Chem. 2001;73(8): 1381-1386.
18. Hubert P, Chiap P, Crommen J, et al. The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington Conference to the laboratory. Anal Chim Acta. 1999;391(2):135-148.
19. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75(13):3019-3030.
20. BIPM. Joint Committee for Guides in Metrology (JCGM), Bureau of Weights and Measures (BIPM). International vocabulary of metrology-Basic and general concepts and associated terms (VIM). Vol JCGM 200:2012: Joint Committee for Guides in Metrology, Bureau of Weights and Measures (BIPM); 2012. Available from: http://www.bipm.org/utils/common/documents/jcgm/JCGM_200_2012.pdf. Accessed June 2, 2013.
21. Currie LA. Nomenclature in evaluation of analytical methods including detection and quantification capabilities (IUPAC Recommendations 1995). Pure Appl Chem. 1995;67(10):1699-1723.
22. Rezende VM, Rivellis AJ, Gomes MM, et al. Determination of serum imatinib mesylate in chronic myeloid leukemia patients: validation and application of a new analytical method to control therapy adherence. Rev Bras Hematol Hemoter. 2013;35(2):103-108.
23. Annesley TM. Ion suppression in mass spectrometry. Clin Chem. 2003;49(7):1041-1044.
24. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003;102(1):83-86.
25. Cortes JE, Baccarani M, Guilhot FO, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28(3): 424-430.
26. Parrillo-Campiglia S, Ercoli MC, Umpierrez O, et al. Bioequivalence of two film-coated tablets of imatinib mesylate 400mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clin Ther. 2009;31(10):2224-2232.
27. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111(8): 4022-4028.